Safety and Efficacy Study of CENV3 Vaccine to Protect Against HCV Infection (CENV3)
|ClinicalTrials.gov Identifier: NCT01718834|
Recruitment Status : Unknown
Verified October 2012 by Mostafa K. El Awady, National Liver Institute, Egypt.
Recruitment status was: Recruiting
First Posted : October 31, 2012
Last Update Posted : October 31, 2012
National Liver Institute, Egypt
Information provided by (Responsible Party):
Mostafa K. El Awady, National Liver Institute, Egypt
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||March 2013|
|Estimated Study Completion Date :||March 2013|
El-Awady MK, Tabll AA, Yousif H, El-Abd Y, Reda M, Khalil SB, El-Zayadi AR, Shaker MH, Bader El Din NG. Murine neutralizing antibody response and toxicity to synthetic peptides derived from E1 and E2 proteins of hepatitis C virus. Vaccine. 2010 Dec 6;28(52):8338-44. doi: 10.1016/j.vaccine.2009.11.059. Epub 2009 Dec 6.